A detailed history of Graham Capital Management, L.P. transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Graham Capital Management, L.P. holds 3,937 shares of ITCI stock, worth $337,361. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,937
Previous 4,553 13.53%
Holding current value
$337,361
Previous $311,000 7.72%
% of portfolio
0.01%
Previous 0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$67.99 - $80.84 $41,881 - $49,797
-616 Reduced 13.53%
3,937 $287,000
Q2 2024

Aug 14, 2024

SELL
$64.76 - $79.84 $812,997 - $1 Million
-12,554 Reduced 73.39%
4,553 $311,000
Q1 2024

May 15, 2024

BUY
$64.37 - $75.65 $1.1 Million - $1.29 Million
17,107 New
17,107 $1.18 Million
Q4 2022

Feb 14, 2023

BUY
$44.07 - $54.45 $675,989 - $835,208
15,339 New
15,339 $811,000

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $8.09B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Graham Capital Management, L.P. Portfolio

Follow Graham Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Graham Capital Management, L.P. with notifications on news.